These findings suggest that IL-1 ligands may function as predictive biomarkers for tumor response to cetuximab-based chemotherapy in HNSCC patients and warrants further investigation and validation in larger clinical studies. The gene discussed is IL1B; the disease is head and neck squamous cell carcinoma.